Drug Profile
TF 2-targeted cancer therapy
Alternative Names: Dual modality imaging - Immunomedics; ImmunoTEP; TF2Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator IBC Pharmaceuticals; Immunomedics
- Developer Immunomedics; Nantes University Hospital
- Class Antibody diagnostics; Antineoplastics; Bispecific antibodies; Monoclonal antibodies; Radiopharmaceutical diagnostics
- Mechanism of Action CEACAM5 protein inhibitors; Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II HER2 negative breast cancer; Non-small cell lung cancer; Small cell lung cancer; Thyroid cancer
- No development reported Colorectal cancer
Most Recent Events
- 08 Sep 2021 No development reported - Phase-II for Colorectal cancer (Diagnosis) in France (IV) (Gilead pipeline, September 2021)
- 03 Dec 2020 Immunomedics withdraws a phase I trial prior to enrolment for colorectal cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease in USA (NCT01273402)
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences